Vimarsana
Biggest News Aggregation in the World

Page 15 - Mark Eisner News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Mark Eisner. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Mark Eisner Today - Breaking & Trending Today

FibroGen, Inc.'s (FGEN) CEO Enrique Conterno on Q1 2022 Results - Earnings Call Transcript - Vimarsana News

FibroGen, Inc.'s (FGEN) CEO Enrique Conterno on Q1 2022 Results - Earnings Call Transcript

FibroGen, Inc. (NASDAQ:NASDAQ:FGEN) Q1 2022 Earnings Conference Call May 09, 2022 5:00 PM ET Company Participants Michael Tung – Corporate Strategy/Investor Relations Enrique Conterno –...

Star Tours: The Making of Disney's Classic Star Wars Ride - Vimarsana News

Star Tours: The Making of Disney's Classic Star Wars Ride

Star Tours, a unique collaboration between Disney and Lucasfilm, first opened in Disneyland 35 years ago this month, and here's a complete history.

Beyond the fiction of Alborada – II - Vimarsana News

Beyond the fiction of Alborada – II

By Sarath Chandrajeewa (Part I of this article appeared in Satmag of 04 Dec.) Allegations about Chilean Ambassador In his book ‘Memoirs’ Neruda openly admits to having sexual relations with a Tamil female labourer, engaged in what was considered the lowest of professions in society of the time, while he was the Chilean Ambassador to […]

Source: island.lk
Astellas Receives European Commission Approval for First-in-Class EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease - Vimarsana News

Astellas Receives European Commission Approval for First-in-Class EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno,...

Astellas Receives European Commission Approval for - Vimarsana News

Astellas Receives European Commission Approval for

Roxadustat is the first orally administered hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) inhibitor available for adult patients with anemia...